CRACD is mutated in 11-16% of SCLC patient tumors and cell lines, ranking after RB1 and TP53 but more frequently than RBL2, CREBBP, and EP300 among validated tumor suppressor genes (Supplementary Fig. S1a–d)21–24. Here, TP53 is linked to small cell lung carcinoma.